Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma

Daphne C Richter, James R Joubert, Haylene Nell, Mace M Schuurmans, Elvis M Irusen, Daphne C Richter, James R Joubert, Haylene Nell, Mace M Schuurmans, Elvis M Irusen

Abstract

Objective: The GOLD guidelines suggest that the presence of a post-bronchodilator forced expiratory volume in one second (FEV1) < 80% of the predicted value in combination with a FEV1/forced vital capacity (FVC) < 70% confirms the diagnosis of COPD. Limited data exist regarding the accuracy of these criteria to distinguish between COPD and asthma. The aim of this study therefore was to investigate the diagnostic value of post-bronchodilator lung function parameters in obstructive lung disease.

Methods: The pulmonary function tests of 43 (22 = COPD, 21 = asthma) patients with similar baseline characteristics were evaluated (baseline FEV were 55.7% +/- 7.6%, and 59.3% +/- 8.4% predicted for COPD and asthma, respectively). Bronchodilator responsiveness (BDR) was calculated according to three recognized pulmonary function test criteria.

Results: The first criteria, post-bronchodilator FEV1 < 80% of the predicted value in combination with a post-bronchodilator FEV1/FVC ratio of < 70%, had an accuracy of 70% to diagnose COPD. This combination was very sensitive (100%) in diagnosing COPD, but it was not specific (38%). The second BDR criteria, defined as an increase of < 12% and 200 mL of initial FEV1 and criterion number 3, an increase of < 9% of predicted FEV1, were less sensitive (55% and 59%, respectively), but more specific (81% and 76% respectively) to diagnose COPD. Our findings suggest that the current recommended spirometric indices are not optimal in differentiating between COPD and asthma.

Figures

Figure 1
Figure 1
Post bronchodilator FEV1 % predicted ( ) and FEV1/FVC ratio ( ) with horizontal bars indicating confidence limits for means at 95% confidence interval.
Figure 2
Figure 2
Bronchodilator response expressed as an increased percentage from initial FEV1 ( ) and as an increase percentage from the predicted FEV1 ( ). Horizontal bars indicate confidence limits for means at 95% confidence interval.

References

    1. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202–18.
    1. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1994;152:1107–36.
    1. Brand PLP, Quanjer PH, Postma DS, et al. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax. 1992;47:429–36.
    1. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004;24:122–8.
    1. Calverley PMA, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58:659–64.
    1. Calverley PMA, Walker P. Chronic obstructive pulmonary disease. Lancet. 2003;362:1053–61.
    1. Celli BR, Halbert RJ, Isonaka S, et al. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22:268–73.
    1. Celli BR. The importance of spirometry in COPD and asthma. Effect on approach to management. Chest. 2000;117:15–9.
    1. Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma. 2005;42:367–72.
    1. Cochrane GM, Prieto F, Clark TJH. Intrasubject variability of maximal expiratory flow volume curve. Thorax. 1977;32:171–6.
    1. Dompeling E, van Schayck CP, Molema J, et al. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. Eur Respir J. 1992;5:975–81.
    1. Dow L. Asthma versus chronic obstructive pulmonary disease – exploring why “reversibility versus irreversibility” is no longer an appropriate approach. Clin Exp Allergy. 1999;29:739–43.
    1. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric and anthropometric variables. Am Rev Respir Dis. 1985;132:858–64.
    1. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418–24.
    1. Jeffrey PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax. 1998;53:129–36.
    1. Knudson RJ, Lebowitz MD, Holberg CJ. Changes in the normal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725–34.
    1. McCarthy DS, Craig DB, Cherniack RM. Intraindividual variability in maximal expiraoty flow-volume and closing volume in asymptomatic subjects. Am Rev Respir Dis. 1975;112:407–11.
    1. Meslier N, Racineux JL, Six P, et al. Diagnostic value of chronic obstruction to separate asthma from chronic bronchitis: a statistical approach. Eur Respir J. 1989;2:497–505.
    1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020. Global Burden of Disease Study. Lancet. 1997;349:1498–504.
    1. Newton MF, O’Donnell DE, Forkert L. Responses of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002;121:1042–50.
    1. O’Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful? Chest. 2000;117:42–7.
    1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease [GOLD] Workshop summary. Am J Resp Crit Care Med. 2001;163:1256–76.
    1. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest. 1998;114:1607–12.
    1. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6:5–40.
    1. Quedrelli SA, Roncoroni AJ, Montiel GC. Assessment of respiratory function: influence of spirometry reference values and normality criteria selection. Respir Med. 1999a;93:523–35.
    1. Quedrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med. 1999b;93:630–6.
    1. Sterk PJ. Let’s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J. 2004;23:497–8.
    1. Tweeddale PM, Alexander F, McHardy GJR. Short term variability and bronchodilator responsiveness in patients with obstructive in FEV1 ventilatory defects. Thorax. 1987;42:487–90.
    1. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airways obstruction in a general population. European Respiratory Society vs American Thoracic Society definition. Chest. 2000;117:339–45.
    1. Weir DC, Burge PS. Measures of reversibility in response to bronchodilators in chronic airflow obstruction: relation to airway caliber. Thorax. 1991;46:43–5.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera